Under liquidation, owners and financials
CVR: 29603537
Secondary names: NovoHansen A/S, HansenNovo A/S
Previous names: NOVOZYMES BIOTECHNOLOGY A/S, NOVOZYMES BIOPHARMA DK A/S, Albumedix A/S
DKK 17,728,465
Gross profit
Net result: DKK 13,735,341
NOVOZYMES A/S (100%)
CVR · view owners
Mikkel Viltoft
CVR · view management
Under liquidation
Founded 29 May 2006
CVR · view overview
0 employees
CVR · 2018
Director role ended: Mikkel Viltoft
CVR · 22/05/2026
View the full event history
Novozymes Biopharma DK A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2006. The company is in liquidation. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Albumedix A/S and NOVOZYMES BIOPHARMA DK A/S. The management consists of Mikkel Viltoft. The company is owned by NOVOZYMES A/S. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK 17,728,465 and a net result of DKK 13,735,341 compared with DKK 11,543,009 the year before. Equity in the 2025 report amounted to DKK 29,725,530.
Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder lægemidler, bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | 13.7 mio. | 33.6 mio. | 29.7 mio. | - | |
| 202401/01/2024 – 31/12/2024 | - | 11.5 mio. | 29.4 mio. | 23 mio. | - | |
| 202301/01/2023 – 31/12/2023 | - | 14.9 mio. | 75.9 mio. | 71.4 mio. | - | |
| 202201/01/2022 – 31/12/2022 | - | 266.1 mio. | 323 mio. | 321.5 mio. | 0 | |
| 202101/01/2021 – 31/12/2021 | - | 51.1 mio. | 123.2 mio. | 108.5 mio. | 0 | |
| 202001/01/2020 – 31/12/2020 | - | 41.2 mio. | 167.5 mio. | 97.4 mio. | 0 | |
| 201901/01/2019 – 31/12/2019 | 0 | 247.7 mio. | 542.4 mio. | 356.2 mio. | 0 | |
| 201801/01/2018 – 31/12/2018 | 65.8 mio. | 65.2 mio. | 120.5 mio. | 108.5 mio. | - | |
| 201701/01/2017 – 31/12/2017 | 150.1 mio. | 132.8 mio. | 91.7 mio. | 43.3 mio. | - | |
| 201601/01/2016 – 31/12/2016 | 152 mio. | 170.7 mio. | 420.6 mio. | 373.9 mio. | - | |
| 201501/01/2015 – 31/12/2015 | 89.7 mio. | -57.1 mio. | 1.5 mia. | 202 mio. | - |
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreNovozymes Biopharma DK A/S is registered in the Danish CVR register with the status Under liquidation.
The CVR number of Novozymes Biopharma DK A/S is 29603537.
Novozymes Biopharma DK A/S is owned by NOVOZYMES A/S.
The management of Novozymes Biopharma DK A/S consists of Mikkel Viltoft.
In 2025, Novozymes Biopharma DK A/S reported a gross profit of DKK 17,728,465.
Novozymes Biopharma DK A/S had 0 employees in 2018 according to the Danish CVR register.
On September 7, 2026, Novozymes Biopharma DK A/S entered liquidation.
Contact info changed: new phone: 44460000 (June 4, 2026).
Novozymes Biopharma DK A/S has published its annual report for 2025. Gross profit came to DKK 17,728,465, and the net result was DKK 13,735,341.
As of May 22, 2026, Mikkel Viltoft has left the board of directors of Novozymes Biopharma DK A/S.
As of May 22, 2026, Lisbet Kragelund has left the board of directors of Novozymes Biopharma DK A/S.
As of May 22, 2026, Rainer Chapour Lehmann has left the board of directors of Novozymes Biopharma DK A/S.
As of May 22, 2026, Mikkel Viltoft is registered as liquidator of Novozymes Biopharma DK A/S.
As of May 22, 2026, Mikkel Viltoft has stepped down as director of Novozymes Biopharma DK A/S.
On May 22, 2026, Novozymes Biopharma DK A/S entered liquidation.
Novozymes Biopharma DK A/S has published its annual report for 2024. Gross profit came to DKK 12,771,174, and the net result was DKK 11,543,009.
As of September 18, 2024, Lisbet Kragelund has joined the board of directors of Novozymes Biopharma DK A/S.
As of September 18, 2024, Randi Camilla Kinch Jensen has left the board of directors of Novozymes Biopharma DK A/S.
Novozymes Biopharma DK A/S has published its annual report for 2023. Gross profit came to DKK 911,763, and the net result was DKK 14,907,714.
As of June 7, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of Novozymes Biopharma DK A/S.
As of June 7, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novozymes Biopharma DK A/S.
As of November 2, 2023, Rainer Chapour Lehmann has joined the board of directors of Novozymes Biopharma DK A/S.
As of November 2, 2023, Lars Green has left the board of directors of Novozymes Biopharma DK A/S.
Novozymes Biopharma DK A/S has published its annual report for 2022. Gross profit came to DKK -399,195, and the net result was DKK 266,066,301.
Novozymes Biopharma DK A/S has published its annual report for 2021. Gross profit came to DKK 58,720,432, and the net result was DKK 51,118,946.
Novozymes Biopharma DK A/S has published its annual report for 2020. Gross profit came to DKK 47,194,246, and the net result was DKK 41,162,269.
As of January 18, 2021, Mikkel Viltoft has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 18, 2021, Lars Green has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 18, 2021, Thomas Videbæk has left the board of directors of Novozymes Biopharma DK A/S.
As of January 18, 2021, Tina Sejersgård Fanø has left the board of directors of Novozymes Biopharma DK A/S.
Novozymes Biopharma DK A/S has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK 247,692,855.
Novozymes Biopharma DK A/S has published its annual report for 2018. Revenue came to DKK 65,805,251, and the net result was DKK 65,150,047.
Novozymes Biopharma DK A/S has published its annual report for 2017. Revenue came to DKK 150,069,684, and the net result was DKK 132,786,054.
As of March 1, 2018, Tina Sejersgård Fanø has joined the board of directors of Novozymes Biopharma DK A/S.
As of March 1, 2018, Randi Camilla Kinch Jensen has joined the board of directors of Novozymes Biopharma DK A/S.
As of March 1, 2018, Søren Knud Carlsen has left the board of directors of Novozymes Biopharma DK A/S.
As of March 1, 2018, Joseph Donald deBethizy has left the board of directors of Novozymes Biopharma DK A/S.
As of March 1, 2018, Gunnar Magnus Severus Modée Persson has left the board of directors of Novozymes Biopharma DK A/S.
As of February 28, 2018, Randi Camilla Kinch Jensen has left the board of directors of Novozymes Biopharma DK A/S.
As of February 7, 2018, Mikkel Viltoft is registered as director of Novozymes Biopharma DK A/S.
As of February 7, 2018, Peter Rosholm has stepped down as adm. dir. of Novozymes Biopharma DK A/S.
On February 7, 2018, the company changed its name from Albumedix A/S to Novozymes Biopharma DK A/S.
Novozymes Biopharma DK A/S has published its annual report for 2016. Revenue came to DKK 152,039,850, and the net result was DKK 170,666,968.
On March 7, 2017, the company changed its name from NOVOZYMES BIOPHARMA DK A/S to Albumedix A/S.
Novozymes Biopharma DK A/S has published its annual report for 2015. Revenue came to DKK 89,714,196, and the net result was DKK -57,116,691.
As of January 15, 2016, Søren Knud Carlsen has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Thomas Videbæk has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Joseph Donald deBethizy has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Randi Camilla Kinch Jensen has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Gunnar Magnus Severus Modée Persson has joined the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Benny Dalgaard Loft has left the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Mikkel Viltoft has left the board of directors of Novozymes Biopharma DK A/S.
As of January 15, 2016, Peter Rosholm is registered as adm. dir. of Novozymes Biopharma DK A/S.
As of January 15, 2016, Thomas Videbæk has stepped down as adm. dir. of Novozymes Biopharma DK A/S.
As of January 14, 2016, Thomas Videbæk has left the board of directors of Novozymes Biopharma DK A/S.
As of December 17, 2015, Benny Dalgaard Loft has joined the board of directors of Novozymes Biopharma DK A/S.
As of December 16, 2015, Benny Dalgaard Loft has left the board of directors of Novozymes Biopharma DK A/S.
Novozymes Biopharma DK A/S has published its annual report for 2014.
Novozymes Biopharma DK A/S has published its annual report for 2013.
Novozymes Biopharma DK A/S has published its annual report for 2012.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novozymes Biopharma DK A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of Novozymes Biopharma DK A/S.
As of May 21, 2010, Mikkel Viltoft has joined the board of directors of Novozymes Biopharma DK A/S.
As of May 21, 2010, Kristian Merser has left the board of directors of Novozymes Biopharma DK A/S.
As of November 15, 2007, Kristian Merser has joined the board of directors of Novozymes Biopharma DK A/S.
As of November 15, 2007, Thomas Videbæk has joined the board of directors of Novozymes Biopharma DK A/S.
As of November 15, 2007, Steen Riisgaard has left the board of directors of Novozymes Biopharma DK A/S.
As of November 15, 2007, Thomas Videbæk is registered as adm. dir. of Novozymes Biopharma DK A/S.
As of November 15, 2007, Benny Dalgaard Loft has stepped down as adm. dir. of Novozymes Biopharma DK A/S.
On November 15, 2007, the company changed its name from NOVOZYMES BIOTECHNOLOGY A/S to NOVOZYMES BIOPHARMA DK A/S.
As of December 7, 2006, Benny Dalgaard Loft has joined the board of directors of Novozymes Biopharma DK A/S.
As of December 7, 2006, Per Artur Fredrik Månsson has left the board of directors of Novozymes Biopharma DK A/S.
As of December 7, 2006, Niels Herman Münter has left the board of directors of Novozymes Biopharma DK A/S.
As of December 7, 2006, Benny Dalgaard Loft is registered as adm. dir. of Novozymes Biopharma DK A/S.
As of December 7, 2006, Per Artur Fredrik Månsson has stepped down as adm. dir. of Novozymes Biopharma DK A/S.
As of May 29, 2006, A/S PSE NR. 4820 has been appointed auditor of Novozymes Biopharma DK A/S.
As of May 29, 2006, Steen Riisgaard has joined the board of directors of Novozymes Biopharma DK A/S.
As of May 29, 2006, Per Artur Fredrik Månsson has joined the board of directors of Novozymes Biopharma DK A/S.
As of May 29, 2006, Niels Herman Münter has joined the board of directors of Novozymes Biopharma DK A/S.
As of May 29, 2006, Per Artur Fredrik Månsson is registered as adm. dir. of Novozymes Biopharma DK A/S.
As of May 29, 2006, NOVOZYMES A/S is registered as an owner of Novozymes Biopharma DK A/S with an ownership share of 100%.
Novozymes Biopharma DK A/S was founded on May 29, 2006.
Companies in the same industry and area
CVR 26400260
CVR 40504044
CVR 31412390
CVR 17281402
CVR 37940844
